Susan T Lord

US Patent:

20060174357, Aug 3, 2006

Filed:

Jan 24, 2005

Appl. No.:

11/040117

Inventors:

William Velander - Blacksburg VA, US
Susan Lord - Chapel Hill NC, US
William Drohan - Springfield VA, US
Henryk Lubon - Rockville MD, US
John Johnson - Blacksburg VA, US
Christopher Russell - Hartselle AL, US

International Classification:

A01K 67/027
C07K 14/75

US Classification:

800007000, 800014000, 530383000

Abstract:

A transgenic, non-human mammalian animal is capable of expressing a heterologous gene for human or other recombinant physiologically functional fibrinogen holoprotein or individual subunit chain polypeptides thereof or a modified or fusion fibrinogen in mammary glands of the animals and secreting the expressed product into a body fluid. Methodology employing such a mammal yields recombinant physiologically functional fibrinogens, subunit chain polypeptides thereof, and modified or fusion fibrinogens.

US Patent:

60374578, Mar 14, 2000

Filed:

Jan 31, 1997

Appl. No.:

8/792108

Inventors:

Susan T. Lord - Chapel Hill NC

Assignee:

The University of North Carolina at Chapel Hill - Chapel Hill NC

International Classification:

C07K 122
C07K 118
C07K 1475
C12P 2102

US Classification:

530413

Abstract:

The present invention provides methods of producing recombinant fibrinogen in a long-term mammalian cell culture system. Disclosed is a method for the production of recombinant fibrinogen, comprising: growing mammalian cells that express recombinant fibrinogen in a serum-free medium for a time of at least one month at a level of at least 5. mu. g/ml; and then collecting portions of the conditioned medium at least twice during the culturing time of at least one month, with each portion containing at least 5. mu. g/ml of recombinant fibrinogen. Also disclosed is a method for the production of recombinant fibrinogen, comprising: growing mammalian cells that express recombinant fibrinogen in a serum-free medium at a level greater than 1. mu. g/ml; collecting at least a portion of the conditioned medium, and then purifying the fibrinogen from the medium by anion-exchange chromatography or affinity chromatography. In some embodiments of the invention, the medium is concentrated prior to the step of purifying the fibrinogen.